NovaBridge Biosciences (NBP) Income from Continuing Operations (2019 - 2025)
NovaBridge Biosciences (NBP) posted quarterly Income from Continuing Operations of 72858000.0 for Q4 2025, down 2655.6% year-on-year from 2850918.34 in Q4 2024, and down 967.05% on a QoQ basis from 6828000.0 in Q3 2025.
NovaBridge Biosciences (NBP) Income from Continuing Operations (2019 - 2025) Analysis & Trends
NovaBridge Biosciences (NBP) has reported Income from Continuing Operations for 5 consecutive years, with 72858000.0 the latest figure, recorded in Q4 2025.
- Quarterly Income from Continuing Operations fell 2655.6% year-over-year to 72858000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 88340000.0 (down 112.89% YoY) and the FY2025 annual result came in at 88340000.0, down 112.89% from the prior year.
- Income from Continuing Operations declined to 72858000.0 in Q4 2025 per NBP's latest filing, from 6828000.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for NBP reached as high as 2644000.0 in Q4 2024 and fell as low as 72858000.0 in Q4 2025.
- A 3-year average of 18411363.64 and a median of 8942000.0 in 2024 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations jumped 92.84% — and 2025, when it plunged 2655.6%.
- Year by year, Income from Continuing Operations stood at 36910000.0 in 2023, then soared by 92.84% to 2644000.0 in 2024, then tumbled by 2655.6% to 72858000.0 in 2025.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 72858000.0, 6828000.0, and 5504000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | NovaBridge Biosciences | 389.86 Mn | 389.86 Mn | - | -72.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -72.86 Mn |
| Sep 30, 2025 | -6.83 Mn |
| Jun 30, 2025 | -5.50 Mn |
| Mar 31, 2025 | -3.15 Mn |
| Dec 31, 2024 | -2.64 Mn |
| Sep 30, 2024 | -20.49 Mn |
| Jun 30, 2024 | -8.94 Mn |
| Mar 31, 2024 | -9.42 Mn |
| Dec 31, 2023 | -36.91 Mn |
| Sep 30, 2023 | -8.22 Mn |
| Jun 30, 2023 | -27.56 Mn |
| Dec 31, 2020 | 160.85 Mn |
| Sep 30, 2020 | -82.36 Mn |
| Dec 31, 2019 | -49.46 Mn |
| Sep 30, 2019 | -35.10 Mn |